Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis

European Journal of Heart Failure

Volumn 17, Issue 11, 2015, Pages 1182-1191

  Simpson, Joanne ^a   Castagno, Davide ^b   Doughty, Rob N ^c   Poppe, Katrina K ^c   Earle, Nikki ^c   Squire, Iain ^d   Richards, Mark ^e   Andersson, Bert ^f   Ezekowitz, Justin A ^g   Komajda, Michel ^h   Petrie, Mark C ⁱ   McAlister, Finlay A ^g   Gamble, Greg D ^c   Whalley, Gillian A ^j   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF ALBERTA   (Canada)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^j UNITEC INSTITUTE OF TECHNOLOGY   (New Zealand)

more..

Author keywords

Atrial fibrillation; Heart failure; Heart rate; Preserved ejection fraction; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; MALE; META ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; SURVIVAL; AGED; COMPLICATION; HEART STROKE VOLUME; HYPERTENSION; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; CAUSE OF DEATH; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STATISTICS AS TOPIC; STROKE VOLUME;

EID: 84954503675     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.346     Document Type: Article

References (47)

1. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M,; Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-830.
2. Ahmadi-Kashani M, Kessler DJ, Day J, Bunch TJ, Stolen KQ, Brown S, Sbaity S, Olshansky B,; INTRINSIC RV Study Investigators. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation 2009; 120: 2040-2204.
3. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,;, SHIFT Investigators,. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894.
4. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R,; BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821
5. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised-placebo-controlled study. Lancet 2010; 376: 875-885.
6. Böhm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, Massie BM, Carson PE, McMurray JJ,; I-Preserve Committees and Investigators. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 2014; 16: 778-787.
7. Stewart S, Hart CL, Hole DJ, McMurray JJ,. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002 1; 113: 359-364.
8. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
9. Maisel WH, Stevenson LW,. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D.
10. Swedberg K, Kjekshus J,; CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
11. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LV,. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
12. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA,;, CHARM Investigators,. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47: 1997-2004.
13. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD,; CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59: 1785-1795.
14. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012; 14: 803-869.
15. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP,. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373.
16. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra M, Groenveld HF, Van den Berg MP, Van Gelder IC,; RACE II investigators. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post hoc analysis of the RACE II study. Eur J Heart Fail 2013; 15: 1311-1318.
17. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). Eur Heart J 2012; 33: 1750-1757.
18. Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA, Gamble G, Sharpe N,. Randomized, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. Eur Heart J 2002; 23: 139-146.
19. Andersson B, Hall C,. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail 2000; 6: 208-213.
20. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM,. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53-60.
21. Torp-Pedersen C, Kober L, Carlsen JE, Akkan D, Bruun NE, Dacoronias D, Dickstein K, Haghfelt T, Ohlin H, McMurray JJ,. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 2008; 10: 89-95.
22. Lenzen MJ, Scholte op Reimer WJM, Boersma E, Vantrimpont PJMJ, Follath F, Swedberg K, Cleland J, Komajda M,. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25: 1214-1220.
23. Gotsman I, Zwas D, Planer D, Azaz-Livshits T, Admon D, Lotan C, Keren A,. Clinical outcome of patients with heart failure and preserved left ventricular function. Am J Med 2008; 121: 997-1001.
24. Grigorian Shamagian L, Roman AV, Ramos PM, Veloso PR, Bandin Dieguez MA, Gonzalez-Juanatey JR,. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail 2006; 12: 128-133.
25. McAlister FA, Teo KK, Taher M, Montague TJ, Humen D, Cheung L, Kiaii M, Yim R, Armstrong PW,. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138: 87-94.
26. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC,. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83: 505-510.
27. Huynh BC, Rovner A, Rich MW,. Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective randomized trial. Arch Intern Med 2006; 166: 1892-1898.
28. Tarantini L, Faggiano P, Senni M, Lucci D, Bertoli D, Porcu M, Opasich C, Tavazzi L, Maggioni AP,. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure. Ital Heart J 2002; 3: 656-664.
29. Macín SM, Perna ER, Címbaro Canella JP, Alvarenga P, Pantich R, Ríos N, Farías EF, Badaracco JR,. Differences in clinical profile and outcome in patients with decompensated heart failure and systolic dysfunction or preserved systolic function. Rev Esp Cardiol 2004; 57: 45-52.
30. Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Mortensen LS,. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J 1994; 15: 303-310.
31. Bayes-Genis A, Vazquez R, Puig T, Fernandez-Palomeque C, Fabregat J, Bardaji A, Pascual-Figal D, Ordonez-Llanos J, Valdes M, Gabarrus A, Pavon R, Pastor L, Gonzalez Juanatey JR, Almendral J, Fiol M, Nieto V, Macaya C, Cinca J, Bayes de Luna A,. Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. Eur J Heart Fail 2007; 9: 802-807.
32. Newton JD, Blackledge HM, Squire IB,. Ethnicity and variation in prognosis for patients newly hospitalised for heart failure: a matched historical cohort study. Heart 2005; 91: 1545-1550.
33. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N,. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42: 1793-1800.
34. Pilbrow AP, Palmer BR, Frampton CM, Yandle TG, Troughton RW, Campbell E, Skelton L, Lainchbury JG, Richards AM, Cameron VA,. Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. Hypertension 2007; 49: 322-327.
35. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL,. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550.
36. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN,; Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404-1413.
37. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Hillege HL, Van Veldhuisen DJ,. A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. Int J Cardiol 2006; 109: 95-100.
38. Cullington D, Goode KM, Zhang J, Cleland JF, Clark AL,. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail 2014; 2: 213-220.
39. Atwood JE, Myers J, Sullivan M, Forbes S, Friis R, Pewen W, Callaham P, Hall P, Froelicher V,. Maximal exercise testing and gas exchange in patients with chronic atrial fibrillation. J Am Coll Cardiol 1988; 11: 508-513.
40. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH,. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
41. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
42. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
43. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, Staiger C, Curtin EL, DeMets DL,; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
44. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL,; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199.
45. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD,; Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient-data meta-analysis. Lancet 2014; 384: 2235-2243.
46. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ,. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1: 21-28.
47. Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J,; beta-PRESERVE Study Investigators. Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail 2010; 12: 181-185.